this section referred to as the ‘‘Commission’’) to assess 
the current security and vulnerabilities of the United 
States pharmaceutical supply chain. 
(b) DUTIES.—The duties of the Commission are the 
following: 
(1) Determine concrete timelines and metrics 
for success for the Pharmaceutical Manufacturing in 
America program of the Biomedical Advanced Re-
search and Development Authority to produce ad-
vanced pharmaceutical ingredients for medicines in-
cluded in the essential medicines list. 
(2) Evaluate and identify vulnerabilities in the 
existing United States pharmaceutical supply chain 
that could be exploited by foreign adversaries and 
nonstate actors. 
(3) Review and propose solutions to strengthen 
the domestic pharmaceutical manufacturing work-
force to support increased production of advanced 
pharmaceutical ingredients and finished drugs. 
(4) Assess how Federal health care programs 
(as defined in section 1128B(f) of the Social Secu-
rity Act (42 U.S.C. 1320a–7b(f))), the program es-
tablished under chapter 89 of title 5, United States 
Code, and provider facilities can be used to create a 
viable financial market for domestically made ad-
VerDate Sep 11 2014 
03:50 Aug 02, 2023
Jkt 039200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\H4449.IH
H4449
kjohnson on DSK79L0C42PROD with BILLS
vanced pharmaceutical ingredients and finished drug 
products. 
(5) Review the successes and failures of Oper-
ation Warp Speed and determine if any best prac-
tices for public-private partnerships can be used to 
bolster domestic manufacturing of advanced phar-
maceutical ingredients and finished drug products. 
(6) Estimate the Federal funding necessary to 
catalyze and strengthen domestic pharmaceutical 
manufacturing. 
(7) Identify facilities throughout the United 
States that can be repurposed to produce advanced 
pharmaceutical 
ingredients, 
especially 
advanced 
pharmaceutical ingredients listed on the essential 
medicines list. 
(8) Identify partner countries where advanced 
pharmaceutical ingredients and finished drug prod-
ucts could be manufactured to reduce dependence on 
China and other countries. 
(9) Provide recommendations on legislative and 
regulatory actions that can be taken to address 
vulnerabilities in the United States pharmaceutical 
supply chain and increase the number of manufac-
turers of advanced pharmaceutical ingredients and 
finished drug products in the United States. 
VerDate Sep 11 2014 
03:50 Aug 02, 2023
Jkt 039200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6201
E:\BILLS\H4449.IH
H4449
kjohnson on DSK79L0C42PROD with BILLS
(10) Identify and propose steps that can be 
taken to increase coordination among different Fed-
eral and State programs to increase manufacturing 
of domestic advanced pharmaceutical ingredients 
and finished drug products. 
(c) MEMBERSHIP.— 
(1) IN
GENERAL.—The Commission shall be 
composed of at least 6 but not more than 11 mem-
bers as follows: 
(A) The National Security Advisor, who 
shall serve as co-chair. 
(B) The White House Domestic Policy 
Council, who shall serve as co-chair. 
(C) The Secretary of Health and Human 
Services. 
(D) The Secretary of Defense. 
(E) The Secretary of State. 
(F) The Secretary of Commerce. 
(G) Not more than 5 members as may be 
appointed by joint action of the co-chairs of the 
Commission, from among the employees and of-
ficers of appropriate Federal departments and 
agencies. 
(2) TERMS.—Each member shall be appointed 
for the life of the Commission. 
VerDate Sep 11 2014 
03:50 Aug 02, 2023
Jkt 039200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6201
E:\BILLS\H4449.IH
H4449
kjohnson on DSK79L0C42PROD with BILLS
(3) QUORUM.—A majority of the Commission 
shall constitute a quorum but a lesser number may 
hold hearings. 
(d) POWERS
OF COMMISSION.—The Commission 
may, for the purpose of carrying out this Act, hold hear-
ings, sit and act at times and places, take testimony, and 
receive evidence as the Commission considers appropriate. 
(e) REPORTS.— 
(1) IN GENERAL.—Not later than 1 year after 
the date of enactment of this Act, and annually 
thereafter until the date of the termination of the 
Commission under subsection (f), the Commission 
shall submit to Congress a report detailing the find-
ings, conclusions, and recommendations of the Com-
mission in fulfilling its duties under subsection (b). 
(2) FORM OF REPORTS.—The reports described 
in paragraph (1) shall be submitted in unclassified 
form but may include a classified annex. 
(f) TERMINATION.—The Commission shall terminate 
on the date that is 4 years after the date of enactment 
of this Act. 
(g) ESSENTIAL MEDICINES LIST DEFINED.—In this 
section, the term ‘‘essential medicines list’’ means the list 
VerDate Sep 11 2014 
03:50 Aug 02, 2023
Jkt 039200
PO 00000
Frm 00005
Fmt 6652
Sfmt 6201
E:\BILLS\H4449.IH
H4449
kjohnson on DSK79L0C42PROD with BILLS
of the Food and Drug Administration described in section 
3(c) of Executive Order 13944. 
Æ 
VerDate Sep 11 2014 
03:50 Aug 02, 2023
Jkt 039200
PO 00000
Frm 00006
Fmt 6652
Sfmt 6301
E:\BILLS\H4449.IH
H4449
kjohnson on DSK79L0C42PROD with BILLS